Alexander Ford Sells 3,031 Shares of Myriad Genetics, Inc. (MYGN) Stock

Myriad Genetics, Inc. (NASDAQ:MYGN) insider Alexander Ford sold 3,031 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) traded down $0.11 on Thursday, hitting $31.25. The stock had a trading volume of 1,062,500 shares, compared to its average volume of 1,220,785. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $37.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. The company has a market cap of $2,171.39, a price-to-earnings ratio of 28.77, a price-to-earnings-growth ratio of 1.99 and a beta of 0.24.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The company had revenue of $190.20 million for the quarter, compared to analyst estimates of $183.52 million. During the same quarter last year, the company posted $0.23 EPS. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. equities analysts expect that Myriad Genetics, Inc. will post 1.05 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Alexander Ford Sells 3,031 Shares of Myriad Genetics, Inc. (MYGN) Stock” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/11/16/alexander-ford-sells-3031-shares-of-myriad-genetics-inc-mygn-stock.html.

A number of research firms have recently issued reports on MYGN. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price objective for the company in a research report on Tuesday, October 17th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $23.00 price objective (up from $21.00) on shares of Myriad Genetics in a research report on Thursday, August 10th. Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price objective on shares of Myriad Genetics in a research report on Sunday, September 17th. Deutsche Bank AG raised Myriad Genetics from a “sell” rating to a “hold” rating and cut their price objective for the company from $27.86 to $15.00 in a research report on Friday, August 18th. Finally, Stephens reaffirmed an “overweight” rating and issued a $40.00 price objective (up from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.10.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. lifted its holdings in Myriad Genetics by 45.0% during the 1st quarter. UBS Asset Management Americas Inc. now owns 34,364 shares of the company’s stock worth $660,000 after buying an additional 10,667 shares during the period. FMR LLC lifted its holdings in Myriad Genetics by 1.5% during the 1st quarter. FMR LLC now owns 403,900 shares of the company’s stock worth $7,755,000 after buying an additional 5,900 shares during the period. Teachers Advisors LLC lifted its holdings in Myriad Genetics by 1.1% during the 1st quarter. Teachers Advisors LLC now owns 116,924 shares of the company’s stock worth $2,245,000 after buying an additional 1,287 shares during the period. Vanguard Group Inc. lifted its holdings in Myriad Genetics by 16.8% during the 1st quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after buying an additional 897,287 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Myriad Genetics by 3.0% during the 1st quarter. Geode Capital Management LLC now owns 661,307 shares of the company’s stock worth $12,696,000 after buying an additional 19,251 shares during the period.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply